What's hot

View all perspectives
      OP0048 Impressive CLASI (lupus skin index score) with #deucravacitinib - data presented by Dr C Arriens #EULAR24 @RheumN

      TheDaoIndex KDAO2011

      1 year 4 months ago
      OP0048 Impressive CLASI (lupus skin index score) with #deucravacitinib - data presented by Dr C Arriens #EULAR24 @RheumNow #WiR https://t.co/EuQdwuolN6
      What is new in RA at #EULAR2024?

      Below 👇🏻 my article summarising some of the exciting new MoA, therapeutic strate

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      What is new in RA at #EULAR2024? Below 👇🏻 my article summarising some of the exciting new MoA, therapeutic strategies and drugs that might (or not) shape RA future! https://t.co/ttYdElWlBY @RheumNow
      🚨New(ish) MoA in RA
      Abiprubart anti-CD40 mAb
      Blocks T cell activation
      Reduction DAS28-CRP Wk 12 -2.2 vs. -1.6 PBO
      Sm

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      🚨New(ish) MoA in RA Abiprubart anti-CD40 mAb Blocks T cell activation Reduction DAS28-CRP Wk 12 -2.2 vs. -1.6 PBO Small sample n=25 per gpe Safety profile acceptable To be continued... Abstr#OP0036 #EULAR2024 @RheumNow https://t.co/su4L7A7nGJ
      Substudy of SELECT-COMPARE trial
      Week 60 immunogenicity RZV RA treated UPA 15 mg + MTX
      ✔️ HUmorale response 71%
      ✔?

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      Substudy of SELECT-COMPARE trial Week 60 immunogenicity RZV RA treated UPA 15 mg + MTX ✔️ HUmorale response 71% ✔️ Cellular response 65% ✔️ No serious AEs ✔️ One event of HZ occurred during follow up Abstr#OP0020 #EULAR2024 @RheumNow https://t.co/8OMwGuIZFx
      Novel B cell depleters! Bispecific T cell engagers (BiTEs) being studied for #SLE & #RA as a way to get CAR-T cell

      TheDaoIndex KDAO2011

      1 year 4 months ago
      Novel B cell depleters! Bispecific T cell engagers (BiTEs) being studied for #SLE & #RA as a way to get CAR-T cell like responses but more accessible w/less risk for CK release syndrome. #EULAR24 T cell-engaging therapies — BiTEs and beyond | Nature Reviews Clinical Oncology
      I chaired great debate at #EULAR2025 - JAK Inhibitor Special Warnings: can observational data debunk an RCT? Drs Janet P

      Dr. John Cush RheumNow

      1 year 4 months ago
      I chaired great debate at #EULAR2025 - JAK Inhibitor Special Warnings: can observational data debunk an RCT? Drs Janet Pope(NO) vs David Liew(YES). Voting suggests most are concerned about JAK warnings, but Liew won by converting a minority his way @janetbirdope @Drdavidliew https://t.co/bV1JdO7c4e
      Nordic country analysis of mortality in RA (n 1145), RA-ILD (239), population ILD (378) & nl controls (1890) shows m

      Dr. John Cush RheumNow

      1 year 4 months ago
      Nordic country analysis of mortality in RA (n 1145), RA-ILD (239), population ILD (378) & nl controls (1890) shows most mortality in pop ILD (HR 8.3), but less in RA-ILD (HR 3.6). Why is death less in latter; could it be RA therapies? Abstr #POS0022 # EULAR2025 https://t.co/wFZq49rIiW
      ✨ Powerful stories shared at the #EULAR2024 Opening Ceremony including from #PARE Chair @fibrofella https://t.co/Jzfk9

      Mrinalini Dey DrMiniDey

      1 year 4 months ago
      ✨ Powerful stories shared at the #EULAR2024 Opening Ceremony including from #PARE Chair @fibrofella https://t.co/Jzfk9LrhV4
      EULAR 2024 kicked off with a fantastic debate between Janet Pope and David Liew - ‘JAK inhibitor special warnings: Can

      The Immune-Mediated Inflammatory Disease Forum IMIDforum

      1 year 4 months ago
      EULAR 2024 kicked off with a fantastic debate between Janet Pope and David Liew - ‘JAK inhibitor special warnings: Can observational data debunk an RCT?’ A thought-provoking discussion summarising all aspects of the ongoing conversation on JAKi use in high-risk patients! https://t.co/MzW3jSSCfr
      More data from Jak-pot, the real-world multinational RA study, this time looking at infection in 14 national registries

      David Liew drdavidliew

      1 year 4 months ago
      More data from Jak-pot, the real-world multinational RA study, this time looking at infection in 14 national registries JAKi (vs TNFi) had no signal for general/serious infection (excluding HZ) Somewhat reassuring post-ORAL Surveillance infection data #EULAR2024 OP0092 @RheumNow https://t.co/ocAbc4NiV2
      Extra musculoskeletal manifestations (EMMs) in spondyloarthritis #EULAR2024 OP0085 @RheumNow https://t.co/yRxPmMYLxn

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      Extra musculoskeletal manifestations (EMMs) in spondyloarthritis #EULAR2024 OP0085 @RheumNow https://t.co/yRxPmMYLxn
      #EULAR2024 Please find my article on a preview of interesting abstract to look out for for #lupus #SLE therapies at this

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      #EULAR2024 Please find my article on a preview of interesting abstract to look out for for #lupus #SLE therapies at this year’s congress @RheumNow https://t.co/TEtrDWq3BF https://t.co/1zIIxsaeL2
      Increase in mSASSS over time was greater with increasing comorbidity burden. Increasing comorbidity burden is independen

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      Increase in mSASSS over time was greater with increasing comorbidity burden. Increasing comorbidity burden is independently associated with greater radiographic progression #EULAR2024 OP0103 @RheumNow https://t.co/j7UblASUvC
      SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, ha

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085 @RheumNow https://t.co/c2KdzIumc4
      Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was highe

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024 @RheumNow https://t.co/vr5DvNOb21

      Podcasts

      • EULAR 2024 SLE Topic Panel
      • EULAR 2024 Psoriatic Arthritis Topic Panel
      • EULAR 2024 Rheumatology Roundup

      Catch up on Conference Podcasts

      ×